Podcasts about Biomarker

In a discussion with CancerNetwork®, Jacob Sands, MD, assistant professor of Medicine at Harvard Medical School, thoracic oncologist at the Dana-Farber Cancer Institute, and investigator of the phase 2 TROPION-Lung05 trial (NCT04484142) and phase 3 TROPION-Lung01 trial (NCT04656652), which supported the accelerated approval of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) in pretreated EGFR-mutant metastatic NSCLC in June 2025, discussed safety and efficacy considerations for the agent's use.1-3 He began by outlining a combined cohort of the TROPION-Lung05 and TROPION-Lung01 trials, which collectively showed an efficacy benefit with dato-DXd in patients with EGFR-mutant disease vs docetaxel. In the combined cohort, the median progression-free survival with dato-DXd reached 5.8 months, and the median overall survival was 15.6 months. Additional efficacy data revealed an objective response rate of 45% (95% CI, 35%-54%) and a median duration of response of 6.5 months (95% CI, 4.2-8.4).  Furthermore, Sands highlighted the most common toxicities observed with dato-DXd in this population, which included stomatitis, interstitial lung disease (ILD), and ocular toxicities. He also reviewed management strategies to mitigate their incidence and severity. Specifically, remedies include prophylaxis, oral hygiene, and dose reductions for stomatitis; using preservative-free eye drops and ophthalmology visits for ocular toxicity management and prevention; and monitoring for any incidence of high-grade ILD. He then touched upon next steps for research in this disease state, including the phase 2 ORCHARD trial (NCT03944772) evaluating dato-DXd with osimertinib (Tagrisso) in the second-line setting after progression on osimertinib and the phase 3 TROPION-Lung15 trial (NCT06417814), which is evaluating chemotherapy vs dato-DXd alone or with osimertinib.4,5 Sands concluded by discussing the implications for toxicity management in patients who experience responses that exceed median outcomes, suggesting that the toxicity profile may be more severe for this group. Emphasizing the broadness of outcomes with any drug, he expressed that patients with experiences that deviate from the observed median outcome are an important consideration for clinical practice. References Sands J, Ahn MJ, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. Published online January 6, 2025. doi:10.1200/JCO-24-01349 Ahn MJ, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. Published online September 9, 2024. doi:10.1200/JCO-24-01544  FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. News release. FDA. June 23, 2025. Accessed July 29, 2025. https://tinyurl.com/mtay7ab9 Yu HA, Goldberg SB, Le X, et al. Biomarker-directed phase II platform study in patients with EGFR sensitizing mutation-positive advanced/metastatic non-small cell lung cancer whose disease has progressed on first-line osimertinib therapy (ORCHARD). Clin Lung Cancer. 2021;22(6):601-606. doi:10.1016/j.cllc.2021.06.006 A study to investigate the efficacy and safety of dato-DXd with or without osimertinib compared with platinum based doublet chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (TROPION-Lung15). ClinicalTrials.gov. Updated July 16, 2025. Accessed July 29, 2025. https://tinyurl.com/56z3dmsp

This episode originally dropped on February 12, 2025.Bill Campbell, PhD, has spent his entire career as a fat loss researcher. So when his wife hit menopause and wanted help with body composition changes, he thought it would be easy. Spoiler alert: It was not. Which made him realize his field had a lot to learn, especially about active women whose bodies change even when their training and nutrition has not. Now he's on a mission, diving into the literature and conducting research of his own to further our understanding of body composition changes during this time of life. We talk all about it, what he's learned, and his work developing a Female Fitness Menopause Survey to learn more.Bill Campbell, PhD is a Professor of Exercise Science and Director of the Performance and Physique Enhancement Laboratory at the University of South Florida. He is also a Certified Strength & Conditioning Specialist from the National Strength & Conditioning Association and former president of the International Society of Sports Nutrition (where he is also 1 of 35 individuals to be recognized as a ‘Fellow' of the organization—an honor reserved for those individuals who have outstanding contributions to the field of sports nutrition). He has published over 200 scientific papers and abstracts, three textbooks, and 20 book chapters in areas related to physique enhancement, sports nutrition, resistance training, and dietary supplementation. You can learn more about him and his work at www.billcampbellphd.comResourcesEstrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial, hereTransdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women, hereMetabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism, herePowerpenia Should be Considered a Biomarker of Healthy Aging, herePurchase the Menopause Course Bundle and Save $111! https://learning.feisty.co/ Sign up for our FREE Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-page Follow Us on Instagram:Feisty Menopause: @feistymenopause Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Support our Partners:Hettas: Use code FEISTY20 for 20% off at https://hettas.com/ Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/ Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ This podcast uses the following third-party services for analysis: Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/Podcorn - https://podcorn.com/privacyPodscribe - https://podscribe.com/privacy

In this podcast we share a few selected highlights from the Alzheimer's Association International Conference (AAIC) pre-conference and first day of the main event in Toronto and Online, 27the - 31st July. -- Dr Tamlyn Watermeyer hosts the show with special guests: Dr Emily Ho, Assistant Professor at Northwestern University Dr Laura Stankeviciute, Postdoctoral Researcher & Scientific Project Manager at University of Gothenburg Joseph Russell, NIHR Research Assistant at Northumbria University -- The AAIC brings together distinguished basic scientists, clinical researchers, early career investigators, clinicians and the care research community at the largest and most influential international conference on dementia science. They share theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Main plenary talk from the day came from Sylvia Villeneuve, Ph.D. Associate Professor, Department of Psychiatry — McGill University, Canada talk about Biomarker and Clinical Trajectories of Preclinical AD. -- #AAIC25 @alzassociation -- Find more information on our guests, and a full transcript of this podcast on our website at: https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

“Next-generation sequencing, or NGS, can be used to help us determine if the patient has specific biomarkers we can identify and use to target for treatment. Certain findings can tell us if a particular treatment might work for that patient, and we can see if there are any genetic variants we might have a biomarker targeted agent to use to treat them with,” ONS member Jackie Peterson, MSN, RN, OCN®, NE-BC, MBA, ambulatory nurse manager at the University of Chicago Medical Center in Illinois, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about prostate cancer and biomarker testing.  This podcast is sponsored by AstraZeneca and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod    Licensed under Creative Commons by Attribution 3.0   Episode Notes This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 180: Learn How Nurse Practitioners Use Biomarker Testing in Cancer Care ONS Voice articles: An Oncology Nurse's Guide to Cascade Testing Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Disorders Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Germline and Somatic Variants: What Is the Difference? Help Patients Understand Genomic Variants of Unknown Significance Prostate Cancer Clinical Trials Don't Reflect Racial Diversity—And It's Getting Worse Over Time Prostate Cancer Disparities Disappear With Equal Access to Care Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations The Case of the Genomics-Guided Care for Prostate Cancer ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing articles: Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management Prostate Cancer: How Nurse Practicioners Can Aid in Disease Diagnosis and Management Oncology Nursing Forum article: Identification of Symptom Profiles in Prostate Cancer Survivors Other ONS Resources: Biomarker Database (refine by prostate cancer or specific biomarkers) Clinical tool/case study: Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Genomics and Precision Oncology Learning Library Huddle Card: Genomic Biomarkers Infographic: Talking to Your Patient About a Germline Variant of Uncertain Significance (VUS) American Cancer Society - Genetic Testing and Counseling for Prostate Cancer Risk American Cancer Society - Prostate Cancer Clinicaltrials.gov National Cancer Institute - Prostate Cancer National Comprehensive Cancer Network ZERO Prostate Cancer To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From This Episode “Some of the risk factors for developing prostate cancer include age, race, family history, and certain genetic changes or variants. Prostate cancer has some hereditary components, but most prostate cancer occurs in men without any significant family history of it.” TS 1:31 “Key biomarkers include PSA and prostate cancer gene 3, which is PCA3, and prostate-specific membrane antigen, or PSMA. Other biomarkers that are important for us to test include BRCA1, BRCA2, and Lynch syndrome–associated genes, which are MLH1, MSH2, MSH6, PMS2, and EPCAM. Biomarkers can be collected via your blood, urine, saliva, or tissue samples, so these are different ways that we can test and look for biomarkers in our patients.” TS 3:24 “It does matter how advanced the disease is. Usually, for our castrate-sensitive patients, they respond better to androgen deprivation therapy because that really is slowing down the growth of the cancer by reducing the available testosterone that the cancer needs to grow. Whereas our patients that are more advanced and have castrate-resistant prostate cancer, that cancer will continue to grow despite having the lowered testosterone levels, so they might need additional layers of treatment to really get their cancer under control.” TS 7:50 “When I talk to [patients] about biomarker testing, I tell them it's another tool in our toolbox that we can use to help us determine if they might benefit from other therapy options now or in the future. I tell them that sometimes we'll get a report back with a variant of unknown significance, and basically that means that we don't really know whether or not this has an impact on their health or risk factors for the disease. That can sometimes be a little bit of a concern for these patients, so we just have to reassure them that we're continually doing research around biomarker testing. The science is always advancing, so if there's something that [researchers] find in the future, we'll make them aware of that.” TS 9:08 “One of the biggest topics I think about is the inequity that exists in biomarker testing and research, especially surrounding the African American population. When these tests were developed, that population really wasn't studied as much, so there's not a lot of good data yet to make a decision or impact on those patients and that population.” TS: 12:30

Sponsor dieser Folge ist Kaneka Erfahre hier mehr: https://www.kaneka-ubiquinol.com/Wir danken Kaneka für die Unterstützung. Die Podcast-Inhalte bleiben aber stets unabhängig, das ist uns wichtig. _______________________________________________________________________________Heute spreche ich mit Professor Eric Verdin, einem der weltweit führenden Altersforscher und Präsidenten des Buck Institute for Research on Aging. Wir sprechen über nichts Geringeres als die Zukunft der Medizin: Wie KI, komplexe Biomarker und präventive Diagnostik unsere Gesundheit revolutionieren könnten – lange bevor Krankheiten entstehen. Eric gibt Einblicke in die PATH-Studie, diskutiert die Potenziale von Ketonkörpern gegen Alzheimer und erklärt, warum GLP-1-Rezeptor-Agonisten als erste globale Anti-Aging-Medikamente gelten könnten. Wissenschaft zum Staunen – verständlich und mitreißend erklärt. In dieser Folge sprechen wir u.a. über folgende Themen: - Wie können KI und Big Data die präventive Medizin revolutionieren? - Warum sind klassische Blutwerte nicht mehr ausreichend für eine moderne Gesundheitsdiagnostik? - Wie lassen sich Herzinfarkt und Alzheimer schon 15 Jahre im Voraus vorhersagen? - Was macht Ketonkörper und Ketoneester zu potenziellen Schutzfaktoren gegen Demenz? - Sind ketogene Diäten alltagstauglich – oder braucht es neue Wege zur Ketose? - Könnten GLP-1-Rezeptor-Agonisten wie Ozempic das erste echte Anti-Aging-Medikament sein? - Warum könnte die Insulinsensitivität der Schlüssel zur Lebensverlängerung sein? - Sind Mäuse als Modellorganismen für die Alternsforschung noch zeitgemäß – oder brauchen wir mehr Humanstudien? - Welche Bedeutung haben Biomarker des Alterns für personalisierte Medizin? - Weshalb wird chronische Entzündung als zentrales Kennzeichen des Alterns angesehen? - Welche Rolle spielt das Immunsystem beim biologischen Altern – und wie können wir es gezielt unterstützen? - Warum ist die Kommunikation wissenschaftlicher Erkenntnisse heute wichtiger denn je? Weitere Informationen zu Prof. Eric Verdin findest du hier: https://www.buckinstitute.org/ Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g Disclaimer: Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin. STY-207

In der morgigen Podcastfolge widmen wir uns dem spannenden Thema gesunde Langlebigkeit – und wie wir Krankheiten erkennen können, bevor sie überhaupt entstehen. Mein Gast ist Prof. Eric Verdin, Präsident des renommierten Buck Institute for Research on Aging. Gemeinsam sprechen wir über bahnbrechende Entwicklungen in der Altersforschung, neue Biomarker, die Rolle von Ketonkörpern und KI in der präventiven Medizin – und darüber, warum Gewichtsverlust-Medikamente wie GLP-1 als echte Anti-Aging-Wunder gelten könnten.  Du interessierst dich für Gesunde Langlebigkeit (Longevity) und möchtest ein Leben lang gesund und fit bleiben, dann folge mir auch auf den sozialen Kanälen bei Instagram, TikTok, Facebook oder YouTube. https://www.instagram.com/nina.ruge.official https://www.tiktok.com/@nina.ruge.official https://www.facebook.com/NinaRugeOffiziell https://www.youtube.com/channel/UCOe2d1hLARB60z2hg039l9g   Disclaimer:  Ich bin keine Ärztin und meine Inhalte ersetzen keine medizinische Beratung. Bei gesundheitlichen Fragen wende dich bitte an deinen Arzt/deine Ärztin.  STY-207 

Early detection of oesophageal adenocarcinoma improves outcomes. Patients with the precursor lesion, Barrett's oesophagus, are recommended to undergo regular endoscopic surveillance, a process that can be burdensome for patients and health services. Professor Rebecca Fitzgerald's team have developed a tool that may be able to improve Barrett's surveillance. She joins us to discuss her recent prospective real-world implementation study of capsule sponge risk stratification in Barrett's oesophagus surveillance in the UK.Read the full article:https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01021-9/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lancetContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Baseline Cardiac Biomarker Levels as Predictors of Cancer Risk in the MESA Cohort.

Mauro Stara is the founder of Six Pack CEO and a peak-performance strategist for time-pressed leaders. Drawing on his background in banking and a science‑driven approach that starts with deep biomarker analysis, Mauro helps CEOs resolve hidden hormonal roadblocks, build cover‑model physiques, and unlock the energy they need to scale their companies without sacrificing health or family life.   https://www.linkedin.com/in/mauro-stara-4b4295217/ https://www.instagram.com/maurostaraofficial/   This podcast is brought to you by LMNT Electrolytes! It's great for a hot summer day, a workout, or just working at your desk with cold water. Check it out and get your free sample pack along with any regular purchase when you use my custom link, www.drinklmnt.com/ScottMys. The LMNT Sample Pack includes one packet of their most popular flavors. This is the perfect offer for 1) anyone who is interested in trying all of our flavors or 2) anyone who wants to introduce a friend to LMNT. Go to www.drinklmnt.com/ScottMys to claim this awesome deal!   Interested in working with me 1-1? I offer personalized coaching where I can help you reach your goals whether it be fat loss, muscle building, health improvements, or all of the above. I provide tailored nutrition, training, and supplementation advice (one or all together) with 24/7 ongoing support to help guide you every step of the way. DM me on Instagram and I can answer any questions. If you like, we can even set up a FREE consult call to go over your goals, answer questions, and discuss what it could look like to work together!

Howie and Harlan are joined by Azita Emami, dean of the Yale School of Nursing, to discuss the school's approach to training nurses who can have a seat at the table of healthcare decision-making. Harlan reports on his new study showing the low levels of evidence required for medical devices in the FDA's Breakthrough Devices Program; Howie provides some good news about infectious diseases including malaria and HIV. Links: Breakthrough devices? Harlan Krumholz: “FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program” FDA: Breakthrough Devices Program “Many medical devices deemed ‘breakthrough' by FDA are backed by patchy evidence” FDA Facts: Biomarkers and Surrogate Endpoints Harlan Krumholz: “Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis” Azita Emami “Americans' Ratings of U.S. Professions Stay Historically Low” “University of Washington selects Azita Emami as dean of School of Nursing” “Azita Emami named new dean of School of Nursing” “The Report of the Rockefeller Foundation on Nursing Education: A Review and Critique” Cleveland Clinic: DHEAS Test “DHEA as a Biomarker of Stress: A Systematic Review and Meta-Analysis” Azita Emami: “Assessing stress using repeated saliva concentration of steroid hormones in dementia care dyads: results from a controlled pilot care music intervention” Azita Emami: “The Feasibility and Acceptability of In-Home Saliva Collection for Stress in Persons With Dementia and Their Family Caregivers” Infectious diseases Mayo Clinic: Malaria WHO: World Malaria Report 2024 “Georgia certified malaria-free by WHO” “Suriname certified malaria-free by WHO” The Global Fund to Fight AIDS, Tuberculosis and Malaria “Novartis wins approval for first malaria drug for newborns and babies” “FDA Approves a Twice-Yearly Shot to Prevent HIV” “U.S. measles cases hit highest level in 33 years, CDC reports” Texas Department of State Health Services: Measles Outbreak “The West Texas measles outbreak has started to slow for the first time since January” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Howie and Harlan are joined by Azita Emami, dean of the Yale School of Nursing, to discuss the school's approach to training nurses who can have a seat at the table of healthcare decision-making. Harlan reports on his new study showing the low levels of evidence required for medical devices in the FDA's Breakthrough Devices Program; Howie provides some good news about infectious diseases including malaria and HIV. Links: Breakthrough devices? Harlan Krumholz: “FDA Authorization of Therapeutic Devices Under the Breakthrough Devices Program” FDA: Breakthrough Devices Program “Many medical devices deemed ‘breakthrough' by FDA are backed by patchy evidence” FDA Facts: Biomarkers and Surrogate Endpoints Harlan Krumholz: “Class I Recalls of Cardiovascular Devices Between 2013 and 2022 : A Cross-Sectional Analysis” Azita Emami “Americans' Ratings of U.S. Professions Stay Historically Low” “University of Washington selects Azita Emami as dean of School of Nursing” “Azita Emami named new dean of School of Nursing” “The Report of the Rockefeller Foundation on Nursing Education: A Review and Critique” Cleveland Clinic: DHEAS Test “DHEA as a Biomarker of Stress: A Systematic Review and Meta-Analysis” Azita Emami: “Assessing stress using repeated saliva concentration of steroid hormones in dementia care dyads: results from a controlled pilot care music intervention” Azita Emami: “The Feasibility and Acceptability of In-Home Saliva Collection for Stress in Persons With Dementia and Their Family Caregivers” Infectious diseases Mayo Clinic: Malaria WHO: World Malaria Report 2024 “Georgia certified malaria-free by WHO” “Suriname certified malaria-free by WHO” The Global Fund to Fight AIDS, Tuberculosis and Malaria “Novartis wins approval for first malaria drug for newborns and babies” “FDA Approves a Twice-Yearly Shot to Prevent HIV” “U.S. measles cases hit highest level in 33 years, CDC reports” Texas Department of State Health Services: Measles Outbreak “The West Texas measles outbreak has started to slow for the first time since January” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.

Wir sprechen über die Top-Interventionen, wichtige Biomarker, die Wahrheit über All-in-One Supplements und den Hype um GLP-1 Agonisten. Außerdem klären wir den Nutzen von Gentests, die besten Tipps zur Hautverjüngung und die Rolle von Wearables.

BUFFALO, NY - July 7, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience.” In this study, a research team led by first author Fei Fei and corresponding author Michelle Afkhami from the City of Hope Comprehensive Cancer Center investigated a rare and aggressive type of blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN). Their research uncovered frequent mutations in key genes and identified CCDC50 as a potential biomarker for diagnosis and disease monitoring. These findings could help improve how this cancer is detected and treated in the future. BPDCN most often affects older adults and is known for its rapid progression and poor survival rates. The researchers performed genetic sequencing on 21 patients to better understand the disease. They found that two genes, TET2 and ASXL1, were frequently mutated in these patients and were linked to worse survival, especially in those over 65 years old. “Our study revealed that TET2 (57%) and ASXL1 (33%) were the most frequently mutated genes, followed by NRAS (29%), SRSF2 (14%), ZRSR2 (14%), and KMT2D (14%).” The study also discovered that a gene called CCDC50 was expressed at much higher levels in BPDCN samples compared to other blood cancers, such as acute myeloid leukemia and chronic monomyelocytic leukemia. This suggests that CCDC50 may help clinicians distinguish BPDCN from other similar diseases. Importantly, CCDC50 levels dropped significantly in patients whose disease went into remission, highlighting its potential as a tool for tracking disease activity over time. Researchers further observed that patients who received stem cell transplants lived longer than those who did not, reinforcing the importance of this treatment approach. However, BPDCN remains a challenging disease with an overall poor outlook, making these findings an important step toward better care. This research provides new insights into the genetic changes behind BPDCN and points to CCDC50 as a promising marker to improve diagnosis and monitor treatment success. Larger studies will be needed to confirm these results and bring these discoveries closer to use in routine medical practice. DOI - https://doi.org/10.18632/oncotarget.28742 Correspondence to - Michelle Afkhami - mafkhami@coh.org Video short - https://www.youtube.com/watch?v=wUjr3uU3onI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28742 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZEV865. CME/MOC/AAPA credit will be available until June 30, 2026.Precision Matters in NSCLC: Everything You Need to Know About Biomarker Testing and Targeted Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation, ONC Brothers. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AbbVie, AstraZeneca, Johnson & Johnson, Lilly, Nuvalent, Nuvation Bio, and Rigel Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was rejoined by Midhun Malla, MD, of the University of Alabama at Birmingham, to discuss therapeutic options for patients with metastatic colorectal cancer (mCRC), particularly in the third-line setting and beyond. In the final part of this 3-part episode miniseries, Drs Park and Malla explored the challenges faced by community oncologists, especially in rural or underserved areas, in accessing clinical trials, which remain a preferred disease management approach due to their role in advancing novel therapies. However, in the absence of trial availability or when patients are ineligible, they emphasized the importance of evidence-based, FDA-approved agents for later lines of therapy. Three primary agents were discussed for patients who have progressed on first-line FOLFOX (folinic acid, fluorouracil, and oxaliplatin) and second-line FOLFIRI (folinic acid, fluorouracil, and irinotecan) regimens: trifluridine/tipiracil (TAS-102; Lonsurf) plus bevacizumab (Avastin); fruquintinib (Fruzaqla); and regorafenib (Stivarga). These agents offer viable treatment pathways in biomarker-unselected patient populations. However, direct comparisons between these agents are lacking, as most were tested against placebo controls. The choice among them is often individualized based on patient performance status, prior exposure to biologics, and toxicity profiles. TAS-102 plus bevacizumab has generated promising results, though real-world data may show diminished efficacy due to frequent prior exposure to 5-fluorouracil and bevacizumab in US patients. Fruquintinib offers a VEGF-targeted approach with a more favorable hematologic toxicity profile, whereas regorafenib is associated with notable adverse effects, including hypertension, gastrointestinal toxicity, and mucositis. Park and Malla emphasized the importance of treatment sequencing, toxicity management, and individualized patient-centered care, including consideration of dose modifications to preserve quality of life in later-line settings. In addition to later-line options, the conversation also touched on emerging frontline therapies. Notable investigational agents include zanidatimab-hrii (Ziihera) and KRAS G12C–directed therapies. Additionally, a novel integrin-targeted cytotoxin is currently under evaluation at the University of Alabama at Birmingham in patients with treatment-naive mCRC. This agent induces apoptosis via caspase-8 activation and has demonstrated encouraging preclinical activity. Overall, the discussion highlighted a nuanced, biomarker-informed, and patient-tailored approach to mCRC management, emphasizing both the value of clinical trials and the importance of optimizing currently available therapies.

Send us a textIn this episode of the WTR Small-Cap | Biotech Spotlight Crossover, Water Tower Research's Tim Gerdeman is joined by Dr. Chris Witowski, CEO of Psilera, and WTR Senior Analyst Robert Sassoon for an insightful discussion on the company's pioneering work in neuroplastogen drug development and delivery technologies.Dr. Chris  Witowski, CEO and Co-Founder of Psilera, an early-stage biotech company focused on developing next-generation neuroplastegens for neurological and neuropsychiatric disorders, shares his thoughts and insights on the evolution of biomarkers in the neurosciences, the latest developments and trends in CNS-focused biomarkers and the potentially transformative impact they will have on the CNS treatment landscape.Tune in to learn more about Psilera's vision for the future of neurotherapeutics and how the company is working to transform the treatment landscape for CNS disorders.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A New Biomarker of Aging Derived From Electrocardiograms Improves Risk Prediction of Incident Cardiovascular Disease.

Please visit answersincme.com/ZDE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in lung cancer discusses best practices for implementing biomarker testing in non-small cell lung cancer (NSCLC) management. Upon completion of this activity, participants should be better able to: Apply current guideline recommendations for biomarker testing to the management of patients with NSCLC, Outline practical strategies within the multidisciplinary team to optimize biomarker testing for patients with NSCLC; and Discuss methods to link biomarker testing to treatment decision-making for patients with NSCLC.

Tired of overpriced marketing tools? Omnisend gives you pro-level automation without draining your wallet. Try it here and see why I made the switch: https://your.omnisend.com/codiesanchez30 Codie and Dr. Rena Malik discuss the complexities of female orgasm, the myths surrounding male sexual performance, and the dynamics of libido in relationships. They delve into the complexities of sexual education, the impact of pornography on young people's understanding of sex, and the importance of open communication between parents and children. The discussion also touches on the future of intimacy in the age of AI and the importance of maintaining human connection. Chapters 00:00 Intro 12:49 The Myths of Male Sexual Performance 26:02 Navigating Libido and Sexual Desire in Relationships 31:17 The Impact of Porn on Sexual Education 35:04 Navigating Conversations About Sex with Kids 39:53 Exploring Personal Sexuality and Preferences 42:55 Sex as a Biomarker of Overall Health 45:51 The Changing Landscape of Sexual Relationships 48:32 Understanding the Pelvic Floor 53:37 The Role of Substances in Sexual Experience 01:00:04 The Future of Intimacy and AI MORE FROM BIGDEAL:

This episode features Prof. Dr. Robert Perneczky who serves as Professor of Translational Dementia Research and Head of Geriatric Psychiatry at Ludwig-Maximilians University in Munich. Dive into the intricate realm of dementia and neurocognitive disorders as he reveals groundbreaking advancements in disease-modifying treatments and emphasizes the crucial role of lifestyle factors in mitigating dementia risk. Explore how cutting-edge innovations in biomarkers and interdisciplinary methodologies are revolutionizing the future of dementia care and gain insightful strategies to enhance resilience against neurodegeneration.

Sie brachten 1925 ein wenig Ordnung in die chaotische Welt der Quanten – allen voran Werner Heisenberg. Ausserdem: Wo steht der Hype um Taurin als Wundermittel gegen das Altern heute? Und: Wir schauen nochmals genau hin, was kam im Lötschental runter, was liegt nun da und was bedeutet das jetzt? (00:00) Schlagzeilen (00:45) Die Geburtsstunde der Quantenmechanik: Vor 100 Jahren brachte der 23-jährige Werner Heisenberg die Quantenmechanik auf der Insel Helgoland aufs Papier. Dorthin war er vor den Pollen gelüchtet. Er lüftet Nase und andere Schleimhäute und offenbar auch seinen Kopf. (07:22) Meldungen: Das ungewisse Schicksal der Wissenschaft in den USA; der Schutz der Nashörner in Südafrika (12:36) Gehyptes Taurin: Vor zwei Jahren wurde Taurin in der Fachzeitschrift Science als Wundermolekül gehypt: Die in zahlreiche biologische Prozesse involvierte Aminosäure verlangsame den Alterungsprozess. Eine neue Science-Studie kommt nun zum gegenteiligen Schluss – Taurin eigne sich nicht als Biomarker fürs Altern. Ein Lehrstück über ein Forschungsfeld, das auch von kommerziellen Interessen getrieben ist. (19:06) Unverrückbare Schutthalde: Beim Bergsturz von Blatten donnerte keine Fels- und Schuttlawine ins Tal, sondern ein Gletscher mit Geröll obendrauf. Dies machte diesen Bergsturz so zerstörerisch und ist mit ein Grund, warum sich der mächtige Schuttkegel über dem Dorf nicht so einfach wegräumen lässt. Welche Rolle spielen Gletscher bei Bergstürzen und wie spielt dabei der Klimawandel mit? Links: Sachbuch: Thomas de Padova, Quantenlicht. Das Jahrzehnt der Physik 1919-1929 hanser-literaturverlage.de/personen/thomas-de-padova-p-1343 Enthornte Nashörner : science.org/doi/10.1126/science.ado7490 Taurin-Studie: science.org/doi/10.1126/science.adl2116

Let's be honest, perimenopause and menopause are incredibly transformative journeys that NONE of us asked for. So, it's up to us to find meaning and purpose amid these shifts.  That's what this episode is all about– finding the power you hold to understand what's really happening in your body at this stage of life.  It's time to decode the symptoms you've been told to brush off again and again by your doctor, and take ACTION that changes your health trajectory today, and for all your days to come. In this episode, I'll provide you with the framework for understanding your body in perimenopause and help you take actionable steps to feel more alive and achieve the results you deserve. We're diving into labs, biomarkers, and how to harness this data to become the ultimate CEO of your health, feeling more confident in your body every day. Tune in here and discover how to reclaim your story and feel empowered every step of the way!  IN THIS EPISODE Why your metabolic health is key to your overall wellness  The 5 biomarkers of optimal metabolic health  Navigating the massive knowledge gap in our healthcare system How to avoid chronic complications down the road  The three truths you need to know about your metabolic health  Understanding your specific lab ranges and analyzing your results  Action steps to find out if you're metabolically healthy  QUOTES “88% of women over 45 years old will have some level of metabolic dysfunction, and insulin resistance is really the silent force behind 8 out of the 10 top causes of death in the US.”  “Metabolic dysfunction and syndrome occur when three or more of the following biomarkers are out of range.” “What a lot of us don't realize is the things that are manifesting in our sixties and seventies really started in our forties. And often they could have been avoided with earlier, more targeted interventions.” RESOURCES MENTIONED The Perimenopause Revolution by Dr. Mariza Snyder: Pre-order your copy here and get IMMEDIATE ACCESS to bonuses like The Perimenopause Power Toolkit, workout videos, recipes & more!  www.qualialife.com/drmariza, Coupon Code: ENERGIZED BEAM Minerals: Use code ENERGIZED at checkout for 20% off your first order! RELATED EPISODES  #648: This Changes Everything: The Perimenopause Revolution Every Woman Needs Now 595: How to Master Your Metabolism and Reverse Cellular Aging in Midlife + My Best Tips to Thrive with Dr. Mariza 584: The Health Costs of Our Modern Life & How to Start Feeling Better with Dr. Casey Means #541: Why Functional Labs Are a Game Changer for Your Health with Dr. Kela Smith

Levels offers biomarker testing to give you more insight into your health status so you can understand the root causes of your symptoms, take a preventive approach to disease, and see if your lifestyle changes or other interventions are reducing your risk factors and improving your health. Dr. Anjali Dsouza and Mike Haney discuss why biomarker testing can be beneficial, how to understand your levels, factors that affect your levels, and which biomarkers are no-brainers to get tested.Sign Up to Get Your Free Ultimate Guide to Glucose: ⁠⁠⁠⁠⁠⁠⁠https://levels.link/wnl⁠⁠⁠⁠⁠⁠Levels helps you see how food affects your health, empowering you with the tools needed to achieve health goals and improve healthspan. Levels Members gain access to the Levels app and continuous glucose monitors (CGMs), providing real-time feedback on how diet and lifestyle choices impact your metabolic health.Look for new shows every month on A Whole New Level, where we have in-depth conversations with thought leaders about metabolic health.

Hosts Mitsuaki Sawano, MD, and co-hosts Kentaro Ejiri, MD, and Satoshi Shoji, MD, are joined by HFpEF expert Hidehiro Yaku, MD, from Northwestern University, for a deep dive into early treatment response to acoramidis, an amyloid stabilizer recently approved in Japan. They discuss its impact on serum transthyretin (sTTR) levels and the emerging role of sTTR as a dynamic biomarker of treatment efficacy. The episode explores the clinical relevance of early sTTR elevation, key insights from the ATTRibute-CM trial—including mediation and logistic regression analyses—and the use of waterfall plots to visualize treatment response. The team also compares acoramidis with tafamidis and vutrisiran, and looks ahead to the evolving therapeutic landscape of ATTR-CM, including gene editing and amyloid removal strategies.

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. Rebecca Whelan, an associate professor of chemistry at the University of Kansas and member of KU Cancer Center's Cancer Biology research program. The discussion focuses on the limitations of the CA125 blood test for ovarian cancer detection and Dr. Whelan's groundbreaking research, which reveals new insights into the structure of the CA125 protein. Dr. Whelan explains how new DNA sequencing technologies and artificial intelligence, specifically the Alpha Fold program, have helped her team improve the understanding and detection of ovarian cancer. Additionally, Dr. Whelan talks about collaborative efforts to identify new biomarkers for early diagnosis of ovarian cancer and shares advice for young scientists interested in making a difference in medicine through chemistry. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about Dr. Whelan's research into CA125 Learn more about ovarian cancer  Read about ovarian cancer screening and diagnosis at KU Cancer Center Learn more about Dr. Rebecca Whelan

In Folge 129 schauen wir uns die Sache mit dem angeblichen Nachweis von Biomarkern auf dem Planeten K2-18b genauer an. Da war zwar jede Menge mediale Aufregung und durchaus coole Wissenschaft. Aber am Ende sind wir weit entfernt von einem Nachweis; es ist sogar fraglich, ob man da überhaupt was beobachtet hat. Außerdem gibt es Buchtipps und Evi erzählt von außerirdischen Yetis im Science Fiction Film. Wenn ihr uns unterstützen wollt, könnt ihr das hier tun: https://www.paypal.com/paypalme/PodcastDasUniversum Oder hier: https://steadyhq.com/de/dasuniversum Oder hier: https://www.patreon.com/dasuniversum

In this three-part series, Jonathan Sackier speaks with Peder Langeland Myhre about cutting-edge advancements in heart failure research, the importance of biomarker-driven care, the challenges of implementing digital health tools globally, and how Norway is reshaping participation in cardiology clinical trials. Timestamps:    00:21 – Biomarker disparities  04:52 – Norway trial challenges  07:15 – Boosting trial engagement 

Dr. Ruben van Eijk is an associate professor in the Department of Neurology at the University Medical Center Utrecht in the Netherlands as well as a statistical consultant and medical statistician for the clinical trial methodology group at the Julius Center also in Utrecht.  Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami.  They will be discussing their recent publication “Rethinking phase 2 trials in amyotrophic lateral sclerosis”.

Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an at-home blood test, cognitive testing, access to neurologists, and education on lifestyle changes that can support a good quality of life. Their mission is to take a proactive rather than the current reactive approach to diagnosing and slowing the progression of cognitive decline.   Rany explains, "The challenge for us, and this is what I saw from years of clinical practice and hospital management, is that a disease like Alzheimer's operates almost like a green light. Life is okay, you're having minor issues, but for the most part, you're moving along. Then suddenly you notice a sentinel event, which then becomes that red light, and now you have Alzheimer's dementia. And so the issue that is at the core of Alzheimer's is early detection. Is there a way for us to detect things earlier and, in turn, provide patients with an opportunity to take control of their dementia and make the necessary changes in treatments?" "In the current setting, the way that we do it in the United States and around the world is really reactive and it is too late by the time your mother or father is developing cognitive complaints. It's very easy to ignore the early stages of it because you can function for three to five years without really anything dramatic happening. So suddenly, when that dramatic instance occurs, for example, you leave the stove on, or you get lost driving back to your house, something that's very obviously outside of the normal, that might trigger you to say, "Let's get Mom checked." "At launch, our focus is on using the biomarker called p-tau 217. This biomarker can be detected now with more technologies in the blood at microscopic levels, and we couldn't do that effectively 10 or 15 years ago. That science has caught up, and the technology has caught up to a point that now, even 8 to 10 years before any significant clinical symptoms occur, we're able to detect if this protein is elevated. Now, if this protein is elevated, depending on the assay that we use, it's about 93%-97% sensitive for potentially developing Alzheimer's long-term. So it's a good protein to use as a triage protein." #NeurogenBiomarkings #Biomarkers #BloodBiomarkers #Alzheimers #AlzheimersDisease #CognitiveDecline #Dementia #EarlyDetection #Neurologists NeurogenBiomarking.com Download the transcript here 

Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, is using a blood-based biomarker looking at p-tau 217 to detect early signs of Alzheimer's disease, up to 8-10 years before the onset of clinical symptoms. The company has built an ecosystem to provide patients with a comprehensive health assessment with an at-home blood test, cognitive testing, access to neurologists, and education on lifestyle changes that can support a good quality of life. Their mission is to take a proactive rather than the current reactive approach to diagnosing and slowing the progression of cognitive decline.   Rany explains, "The challenge for us, and this is what I saw from years of clinical practice and hospital management, is that a disease like Alzheimer's operates almost like a green light. Life is okay, you're having minor issues, but for the most part, you're moving along. Then suddenly you notice a sentinel event, which then becomes that red light, and now you have Alzheimer's dementia. And so the issue that is at the core of Alzheimer's is early detection. Is there a way for us to detect things earlier and, in turn, provide patients with an opportunity to take control of their dementia and make the necessary changes in treatments?" "In the current setting, the way that we do it in the United States and around the world is really reactive and it is too late by the time your mother or father is developing cognitive complaints. It's very easy to ignore the early stages of it because you can function for three to five years without really anything dramatic happening. So suddenly, when that dramatic instance occurs, for example, you leave the stove on, or you get lost driving back to your house, something that's very obviously outside of the normal, that might trigger you to say, "Let's get Mom checked." "At launch, our focus is on using the biomarker called p-tau 217. This biomarker can be detected now with more technologies in the blood at microscopic levels, and we couldn't do that effectively 10 or 15 years ago. That science has caught up, and the technology has caught up to a point that now, even 8 to 10 years before any significant clinical symptoms occur, we're able to detect if this protein is elevated. Now, if this protein is elevated, depending on the assay that we use, it's about 93%-97% sensitive for potentially developing Alzheimer's long-term. So it's a good protein to use as a triage protein." #NeurogenBiomarkings #Biomarkers #BloodBiomarkers #Alzheimers #AlzheimersDisease #CognitiveDecline #Dementia #EarlyDetection #Neurologists NeurogenBiomarking.com Listen to the podcast here 

Naked Gardening Best Cities… NJ Wildfire update and an arson arrest… AJ Brown car (whip) stolen… Jack in the Box closing hundreds of stores…Shannon Sharpe steps away from ESPN… NFL Draft Update… Email: ChewingTheFat@theblaze.com Sperm Race in LA… Blake Lively / Baldoni case ongoing... Golden Globes date... Academy rule changes…www.blazetv.com/jeffy Promo code Jeffy… Mortuary lady testing on bodies… No kidding, Jersey Mike's has new CEO… Game Show: What's The Lie? Family edition / Contestants: Dean & Wesley Castelhano… Learn more about your ad choices. Visit megaphone.fm/adchoices

As blood-based Alzheimer's disease (AD) biomarkers emerge, how can they change primary care's role in AD diagnosis? Credit available for this activity expires: 4/17/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/informing-alzheimers-disease-referral-blood-based-biomarker-2025a10008tl?ecd=bdc_podcast_libsyn_mscpedu

Request Access to the FREE Health Impact SoftwareClick this link. ⁠⁠⁠FREE Health Impact APP⁠⁠⁠No strings attached—we will send an email, and you'll receive an exclusive download link.Take Action:

Thinking Thoracic host Dr. Erin Gillaspie and Dr. Stephen Liu,  associate professor of medicine at Georgetown University and head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center, discuss the surgeon's role in navigating the biomarker space and working collaboratively with oncology colleagues.  

Helena Yu, MD and Joshua Sabari, MD explore the importance of testing for HER2 alterations in lung cancer; how HER2 positivity influences clinical decision-making; and the key methods used for detection, including immunohistochemistry, fluorescence in situ hybridization, and next-generation sequencing. It also addresses challenges in standardizing HER2 testing, disparities in access to biomarker testing, and the evolving role of liquid biopsy compared to traditional tissue biopsy.

For this episode we are joined by EBM guru, Dr. Brian Locke, who deftly breaks down all of our statistics questions. Is half dose DOAC as good as full dose DOAC for preventing VTE, and does it reduce bleeding risk? Can procalcitonin reduce duration of antibiotics for infections without compromising mortality rates? Can LLMs like GPT-4 help physicians manage patients better? Can reinforcement learning models predict when to start vasopressin in patients with septic shock? What is the risk of resuming anticoagulation in patients with atrial fibrillation and prior intracerebral hemorrhage? Is high flow nasal cannula as good as non-invasive ventilation for different types of respiratory failure? We answer all these questions and more!Half Dose DOAC for Long Term VTE Prevention (RENOVE)Biomarker-Guided Antibiotic Duration (ADAPT-Sepsis)GPT-4 Assistance for Physician PerformanceOptimal Vasopressin Initiation for Septic Shock (OVISS)DOACs for A fib after ICH (PRESTIGE-AF)High Flow Nasal Cannula vs NIV for Respiratory Failure (RENOVATE)Music from Uppbeat (free for Creators!): https://uppbeat.io/t/soundroll/dope License code: NP8HLP5WKGKXFW2R

Join me for a fascinating conversation around an exciting breakthrough in dementia detection that's offering real hope for early intervention. Dr. Hans Frykman, Chief Scientific Officer at Neurocode Laboratories, is here to share groundbreaking insights into cutting-edge biomarkers that can identify pathology associated with Alzheimer's disease before symptoms even appear. What's even more fascinating is how these same tools are revealing neuroinflammation caused by infections, including COVID, Lyme disease, and mold exposure—issues that are incredibly relevant in functional medicine today. The assays Dr. Frykman and his team have developed, and continue to research, are transforming the way we think about diagnosing and addressing neurodegeneration. We're talking about a potential game-changer that allows us to intervene earlier, reverse damage, and ultimately improve the trajectory of these conditions. This is an extraordinary time in science and medicine, and the work we're discussing today is at the forefront of it all. Don't miss out on how this could reshape your practice. ~DrKF Check out the show notes at https://tinyurl.com/2t55s3y3 for the full list of links and resources. GUEST DETAILS Dr. Hans Frykman, MD PhD FRCPC hfrykman@neurocode.com Hans Frykman MD, Ph.D., FRCPC is the founder, CEO, and medical director of BC Neuroimmunology Lab located in the UBC hospital on the University of BC campus in Vancouver BC. He is the medical director for Lykke Lab a genetics laboratory also on the University of BC campus. Also, he is the CSO for Neurocode Lab Inc. in Bellingham WA, a high-complexity, specialty lab focused on neuroimmunology and biomarkers in neurodegeneration. Dr. Frykman has a clinical faculty position at the University of British Columbia, Faculty of Medicine, Division of Neurology. THANK YOU TO OUR SPONSORS DIAMOND DUTCH: https://dutchtest.com/for-providers Biotics Research: https://www.bioticsresearch.com/ GOLD TimeLine Nutrition: https://tinyurl.com/bdzx2xms Vibrant Wellness: https://www.vibrant-wellness.com/ EXCLUSIVE OFFERS FROM OUR SPONSORS OneSkin: Get 15% off OneSkin with the code DRKARA at oneskin.co/DRKARA Try Qualia NAD+ for up to 50% off! Visit http://qualialife.com/kara15 and use code KARA15 at checkout for an additional 15% off your entire purchase! Why MitoQ's mitochondria-targeting is a critical step for your healthspan and longevity strategy. https://tinyurl.com/2b5benmd Want more? CONNECT WITH DrKF Join our newsletter here: https://www.drkarafitzgerald.com/newsletter/ Or take our pop quiz and test your BioAge! https://www.drkarafitzgerald.com/bioagequiz YouTube: https://tinyurl.com/hjpc8daz Instagram: https://www.instagram.com/drkarafitzgerald/ Facebook: https://www.facebook.com/DrKaraFitzgerald/ DrKF Clinic: Patient consults with DrKF physicians including Younger You Concierge: https://tinyurl.com/yx4fjhkb Younger You book: https://tinyurl.com/mr4d9tym Better Broths and Healing Tonics book: https://tinyurl.com/3644mrfw

In this episode, Dr. Valentin Fuster summarizes the March 25, 2025, issue of the JACC, which focuses on advancements in electrophysiology. Highlights include groundbreaking studies on leadless pacemakers, atrial fibrillation treatments, and appropriate use criteria for cardiac devices, with key papers exploring the safety of pacemaker retrieval, the role of electrograms in ablation procedures, and long-term outcomes for left atrial appendage occlusion devices.

Bill Campbell, PhD, has spent his entire career as a fat loss researcher. So when his wife hit menopause and wanted help with body composition changes, he thought it would be easy. Spoiler alert: It was not. Which made him realize his field had a lot to learn, especially about active women whose bodies change even when their training and nutrition has not. Now he's on a mission, diving into the literature and conducting research of his own to further our understanding of body composition changes during this time of life. We talk all about it, what he's learned, and his work developing a Female Fitness Menopause Survey to learn more.Bill Campbell, PhD is a Professor of Exercise Science and Director of the Performance and Physique Enhancement Laboratory at the University of South Florida. He is also a Certified Strength & Conditioning Specialist from the National Strength & Conditioning Association and former president of the International Society of Sports Nutrition (where he is also 1 of 35 individuals to be recognized as a ‘Fellow' of the organization—an honor reserved for those individuals who have outstanding contributions to the field of sports nutrition). He has published over 200 scientific papers and abstracts, three textbooks, and 20 book chapters in areas related to physique enhancement, sports nutrition, resistance training, and dietary supplementation. You can learn more about him and his work at www.billcampbellphd.comResourcesEstrogen modulates metabolic risk profile after resistance training in early postmenopausal women: a randomized controlled trial, hereTransdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women, hereMetabolic effects of menopause: a cross-sectional characterization of body composition and exercise metabolism, herePowerpenia Should be Considered a Biomarker of Healthy Aging, hereJoin the Feisty Girona Gravel Camp: https://www.thomsonbiketours.com/trips/feisty-girona-gravel-camp/ Subscribe to the Feisty 40+ newsletter: https://feistymedia.ac-page.com/feisty-40-sign-up-page Follow Us on Instagram:Feisty Menopause: @feistymenopause Hit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099 Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/ Nutrisense: Go to nutrisense.io/hitplay and use code: HITPLAY to get $125 off Previnex: Get 15% off your first order with code HITPLAY at https://www.previnex.com/ This podcast uses the following third-party services for analysis: Spotify Ad Analytics - https://www.spotify.com/us/legal/ad-analytics-privacy-policy/Podcorn - https://podcorn.com/privacyPodscribe - https://podscribe.com/privacy